Apertor develops novel molecular glues using a synthetic biology platform that leverages non-model organisms and a structure-guided computational design pipeline for therapeutic applications in oncology. The company focuses on creating first-in-class treatments for age-related diseases, addressing significant pharmacological challenges in cancer therapy.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer therapies face challenges in selectively targeting cancer cells and effectively modulating protein-protein interactions within the tumor microenvironment. Traditional approaches often lack the precision needed to disrupt specific oncogenic pathways, leading to off-target effects and limited efficacy.
Solution
Apertor develops novel molecular glues designed to address these challenges by selectively modulating protein-protein interactions within cancer cells. Their approach leverages a synthetic biology platform using non-model organisms and a structure-guided computational design pipeline to create first-in-class treatments for oncology. These molecular glues are designed to precisely target and disrupt specific oncogenic pathways, offering a more targeted and effective approach to cancer therapy. The company aims to deliver new, high-value treatment options for patients by solving important pharmacological problems in cancer therapy.
Target Audience
The primary target audience includes oncology researchers and pharmaceutical companies seeking innovative and targeted therapeutic approaches for cancer treatment.
Features
- Synthetic biology platform utilizing non-model organisms for novel molecule discovery
- Structure-guided computational design pipeline for rational drug development
- Focus on creating molecular glues that modulate protein-protein interactions
- Development of first-in-class treatments for oncology
- Targeted approach to disrupt specific oncogenic pathways